Biosimilars Market 2015-2022 by Segmentation Based on Product, Application and Region

Posted May 30, 2017 by kevinspot

Biosimilars Market is expected to grow at the CAGR of 22.6% during 2015-2022.

According to a recently published report, the Biosimilars Market is expected to grow at the CAGR of 22.6% during 2015-2022. The segmentation of global biosimilars market is based on product type, application, technology, services and geography. The report on Global Biosimilars Market Forecast, 2015-2022 (by product type, application, technology, services and geography) provides detailed overview and predictive analysis of the market.
Increasing number of off patented drugs, rising pressure to decrease healthcare expenditure and cost effectiveness are the various factors that are driving the growth of global biosimilars market.

Detailed study on this Research :

Market players are implementing various growth strategies in the market to gain a competitive edge. New product launch, product pipelines, agreements and collaborations were certain major strategies adopted by players. Some of the challenges faced by biosimilars market are fledgling regulatory framework and various manufacturing related issues.

For Same Category Reports Visit Here:

Scope of the report
1. Global Biosimilar market by product type, 2012 – 2022 ($ billion)
1.1. Recombinant Peptides
1.1.1. Glucagon
1.1.2. Calcitonin
1.2. Recombinant Glycosylated Proteins
1.2.1. Erythropoietin (EPO)
1.2.2. Follitropin
1.2.3. Monoclonal Antibodies (MABS)
1.3. Recombinant Non-Glycosylated Proteins
1.3.1. Interferons
1.3.2. Recombinant Human Growth Hormone (RHGH)
1.3.3. Granulocyte Colony-Stimulating Factor (Filgrastim)
1.3.4. Insulin

2. Global Biosimilar market by application type, 2012 – 2022 ($ billion)
2.1. Blood Disorders
2.2. Chronic and Autoimmune Diseases
2.3. Growth Hormone Deficiency
2.4. Infectious Diseases
2.5. Other Applications

3. Global Biosimilar market by technology, 2012 – 2022 ($ billion)
3.1. Nuclear magnetic resonance technology
3.2. Western blotting
3.3. Monoclonal antibodies technology
3.4. Electrophoresis
3.5. Chromatography
3.6. Bioassay
3.7. Recombinant DNA technology
3.8. Mass spectrometry

4. Global Biosimilar market by technology, 2012 – 2022 ($ billion)
4.1. Clinical trials
4.2. Contract research & manufacturing services (CRMS)

5. Global Biosimilar market , regional outlook, 2012-2022(in $billion)
5.1. North America
5.2. Europe
5.3. Asia Pacific
5.4. Middle East & Africa
5.5. Latin America
6. Company profiles
6.1. Amgen
6.2. Biocon Ltd.
6.3. Celltrion, Inc.
6.4. Dr. Reddy’s Laboratories
6.5. Hospira,inc
6.6. Merck KGAA
6.7. Mylan, Inc.
6.8. Roche Diagnostics
6.9. Sandoz International GmbH
6.10. Teva Pharmaceutical Industries Ltd.
6.11. Stada Arzneimittel AG
6.12. Ratiopharm GmbH
6.13. Intas Pharmaceuticals Ltd.
6.14. LG Life Sciences
6.15. Synthon Pharmaceuticals, Inc.

Here you can find Free Sample on this Research :

Blog :

About Us :

Brisk Insights is a global market research firm. Our insightful analysis is focused on developed and emerging markets. We identify trends and forecast markets with a view to aid businesses identify market opportunities optimize strategies.
Working in a highly dynamic and multi-dimensional business makes decision making complex. Effective business decisions are a result of the synthesis of market information. Our Research and data analysis is an efficient and cost-effective way of providing robust market analysis and can yield highly valuable intelligence relating to consumers, competitors and markets.
Contact Us :
Jennifer Smith
Office 1094
109 Vernon House
Friar Lane
Phone : +448081890034 (UK)
Email : [email protected]
Website :
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Brisk Insights
Country United States
Categories Business , Industry
Tags biosimilars market , biosimilars market size , biosimilars market share
Last Updated May 30, 2017